Malta vs New Zealand: Hepatitis B surface antigen (HBsAg) prevalence
Malta
0.0%
in 2024
New Zealand
0.0%
in 2024
Malta rank
132nd
New Zealand rank
132nd
Hepatitis B surface antigen (HBsAg) prevalence over time
- Malta
- New Zealand
How they compare
Malta currently reports 0.0% against 0.0% in New Zealand, a difference of 0.0%.
Across all 10 years both countries report, New Zealand has been ahead every year.
Malta ranks 132nd and New Zealand ranks 132nd of 194 countries.
New Zealand has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Malta | New Zealand | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.0% | 0.1% | 0.1% | New Zealand |
| 2020s | 0.0% | 0.0% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, Malta or New Zealand?
- Malta, at 0.0% against 0.0% in New Zealand as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between Malta and New Zealand?
- 0.0%, with Malta ahead.
- How many years of comparable data are there for Malta and New Zealand?
- 10 years are reported by both, from 2015 to 2024.
- How do Malta and New Zealand rank globally for hepatitis b surface antigen (hbsag) prevalence?
- Malta ranks 132nd and New Zealand ranks 132nd of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.